XML 30 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1

Revenues (Tables)

3 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Summary of net revenue

The Company’s net revenues consisted of the following for the three months ended March 31, 2017 and 2016:

	Three months ended March 31,
	2017				2016
Products:
Acetadote	$	1,265,440			$	1,837,462
Omeclamox-Pak	645,325				760,319
Kristalose	2,386,591				3,617,806
Vaprisol	684,548				368,047
Caldolor	813,027				1,071,968
Ethyol	3,666,808				—
Other	175,016				81,930
Total net revenues	$	9,636,755			$	7,737,532

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration